Key result
Carmustine is linked to ~174% higher reporting of nervous system disorders.
Why the study?
Comprehensive postmarketing evidence on the broader spectrum of adverse event signals related to carmustine remains limited despite its recognized major toxicities.
What are the postmarketing adverse event signals associated with carmustine in the FAERS database?
Population
718 adverse drug reaction reports identifying carmustine as the primary suspect in FAERS
Comparison
Carmustine exposure vs other reports in FAERS
Design
Pharmacovigilance disproportionality analysis
Authors
Loading...
Warrants vigilance for neurotoxic, hematologic, and infectious events; hypothesis-generating and requires prospective validation.
Observational (n=718)
What are the postmarketing adverse event signals associated with carmustine in the FAERS database?
Odds Ratio: 2.74
Carmustine is associated with significant post-marketing safety signals for neurotoxic, hematologic, and infectious complications, with some sex-specific differences.
Xu et al. (2026) conducted an observational in Adverse drug reactions (n=718). Carmustine (BCNU) was evaluated on Nervous system disorders (ROR 2.74). Carmustine exposure was associated with significant reporting signals for nervous system disorders (ROR 2.74), blood and lymphatic system disorders (ROR 2.95), and infections (ROR 2.15).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: